Annals of Oncology 13:1810-1818, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics
1 Division of Haematology and Medical Oncology and 3 Statistical Centre, Peter MacCallum Cancer Institute, Melbourne; 2 Newcastle Mater Hospital, Newcastle; 4 Sydney Cancer Centre, Sydney, Australia; 5 The Australian and New Zealand Breast Cancer Trials Group
Received 19 November 2001; revised 23 April 2002; accepted 13 May 2002;
Background:
The objective of this phase I trial was to determine the maximally tolerated doses of the combination of docetaxel, epirubicin and cyclophosphamide.
Patients and methods:
Patients with advanced cancer, World Health Organization (WHO) performance status 0 to 2, who had received up to one prior chemotherapy regimen were treated with docetaxel, epirubicin and cyclophosphamide repeated every 21 days. The cyclophosphamide dose was fixed at 600 mg/m2 and the dose levels studied were: docetaxel/epirubicin; 60/60, 75/60, 75/75, 75/90, 85/90 and 85/105 mg/m2. There was provision for the addition of prophylactic ciprofloxacin and granulocyte colony-stimulating factor (G-CSF) in separate steps if dose-limiting toxicity (DLT) was neutropenia related.
Results:
Forty-three patients were entered and all were assessable for toxicity. Dose-limiting toxicity, predominantly febrile neutropenia, was surprisingly seen at the first dose level. The addition of prophylactic ciprofloxacin did not permit dose escalation, but dose escalation was possible with the addition of G-CSF. The highest administered dose level with G-CSF was docetaxel 85 mg/m2 and epirubicin 105 mg/m2 with DLTs in five of six patients. Treatment was well tolerated in 10 patients treated at the recommended dose level (85/90) with only one patient experiencing DLT. Responses were seen in a range of malignancies including breast and anaplastic thyroid cancers. No significant pharmacokinetic interaction was observed, but a transient increase in epirubicinol plasma concentration occurred during and after docetaxel infusion.
Conclusions:
The recommended dose level of docetaxel 85 mg/m2, epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 with G-CSF support has a favorable toxicity profile and is suitable for further investigation in phase II and III trials.
Key words: chemotherapy, cyclophosphamide, docetaxel, epirubicin, pharmacology, phase I trials
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Salvatorelli, P. Menna, L. Gianni, and G. Minotti Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Markasz, G. Stuber, B. Vanherberghen, E. Flaberg, E. Olah, E. Carbone, S. Eksborg, E. Klein, H. Skribek, and L. Szekely Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells Mol. Cancer Ther., February 1, 2007; 6(2): 644 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Zhu, E. Gerbino, D. M. Beaupre, P. A. Mackley, C. Muro-Cacho, C. Beam, A. D. Hamilton, M. G. Lichtenheld, W. G. Kerr, W. Dalton, et al. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells Blood, June 15, 2005; 105(12): 4759 - 4766. [Abstract] [Full Text] [PDF]
|
|